AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE Life Science Investing
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy Life Science Investing
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application Life Science Investing
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 Life Science Investing
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 Life Science Investing
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 Life Science Investing
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board Life Science Investing
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive Life Science Investing
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy Life Science Investing
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody in Patients with Microsatellite Stable Colorectal Cancer Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
